U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H32O2
Molecular Weight 316.4776
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Pregnenolone

SMILES

[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4C[C@@H](O)CC[C@]34C

InChI

InChIKey=ORNBQBCIOKFOEO-QGVNFLHTSA-N
InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H32O2
Molecular Weight 316.4776
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:13:51 UTC 2023
Edited
by admin
on Sat Dec 16 17:13:51 UTC 2023
Record UNII
73R90F7MQ8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Pregnenolone
INN   JAN   MI   VANDF   WHO-DD  
INN  
Official Name English
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
Common Name English
NSC-18158
Code English
.DELTA. SUP(5)-PREGNEN-3.BETA.-OL-20-ONE
Common Name English
PREGN-5-EN-20-ONE, 3-(3-CARBOXY-, (3.BETA.)-
Common Name English
PREGNENOLONE [JAN]
Common Name English
PREGNENOLONE [VANDF]
Common Name English
NSC-1616
Code English
ARTHENOLONE
Common Name English
ENELONE
Common Name English
PREGNENOLONE [MI]
Common Name English
Pregnenolone [WHO-DD]
Common Name English
pregnenolone [INN]
Common Name English
3.BETA.-HYDROXYPREGN-5-EN-20-ONE
Systematic Name English
Classification Tree Code System Code
LOINC 13894-1
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
CFR 21 CFR 862.1615
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
NCI_THESAURUS C1636
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
LOINC 17480-5
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
DSLD 1868 (Number of products:84)
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
CFR 21 CFR 310.530
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
LOINC 25507-5
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
LOINC 2837-3
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL2105373
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
DAILYMED
73R90F7MQ8
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
NSC
1616
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
MERCK INDEX
m9121
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY Merck Index
CAS
145-13-1
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
FDA UNII
73R90F7MQ8
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
EVMPD
SUB10024MIG
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID1036541
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
IUPHAR
2376
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
DRUG BANK
DB02789
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-647-4
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
WIKIPEDIA
Pregnenolone (medication)
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
MESH
D011284
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
INN
4178
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
RXCUI
114052
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY RxNorm
CHEBI
16581
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
NSC
18158
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
SMS_ID
100000081407
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
PUBCHEM
8955
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
WIKIPEDIA
PREGNENOLONE
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
NCI_THESAURUS
C82315
Created by admin on Sat Dec 16 17:13:51 UTC 2023 , Edited by admin on Sat Dec 16 17:13:51 UTC 2023
PRIMARY
Related Record Type Details
CANNABINOID RECEPTOR 1
TARGET->NEGATIVE ALLOSTERIC MODULATOR (NAM)
∆9-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor. Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC. This negative feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation.
Related Record Type Details
Structure of CHOLESTEROL
PARENT -> METABOLITE
In steroidogenic tissues
Related Record Type Details
Structure of Pregnenolone
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
BRAIN/PLASMA RATIO PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966